News - Cellvizio - Jul 21, 2022

Mauna Kea Technologies Announces Q2 and 1H 2022 Revenues

Stable YTD Revenue while Strategic Realignment Implemented
35% 1H U.S. Sales Growth offset by Declines in Asia
Recently announced Tasly Pharmaceuticals JV and licensing agreements expected to produce new revenue stream

Mauna Kea Technologies today announced its revenues for the second quarter and first half of 2022 ended June 30, 2022.

Sales for the first half of 2022 increased by €82K, or +2% year-on-year, to €3,397K.

  • Systems sales at €1,294K, +11%.
  • Sales of consumables at €1,419K, -11%.
  • Sales of services at 684 K€, +22%.

After an increase in the first quarter (€1,886K, i.e. +20% compared to the previous year), sales in the second quarter of 2022 were down (€227K), i.e. -13% year-on-year, to €1,511K.

  • Systems sales at 363 K€, -42%.
  • Sales of consumables at 786 K€, -10%.
  • Sales of services at 362 K€, +45%.

Nicolas Bouvier, Interim CEO of Mauna Kea Technologies, said, "When we announced our Strategic Realignment in late-2021, we expressed our intent to meet the clinical and service needs of our legacy Cellvizio users while pivoting our commercial focus to strategic partnerships in new indications, such as we recently announced with Tasly Pharmaceuticals. I am proud of how our team has responded to this dynamic transition and believe our Half-year sales, including 35% y/y U.S. revenue growth, reflect the organization’s disciplined commitment to meeting our near-term objectives while working to ensure Cellvizio is an indispensable technology for improved clinical effectiveness and patient outcomes."

​​​​For additional details and financial results, please see the full press release.